MINNEAPOLIS, Jan. 26, 2021 (GLOBE NEWSWIRE) – Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on the application of artificial intelligence (“ IA ‘) at Personalized Medicine and Drug Discovery, today announced the closing of its previously announced registered direct offering of 3,414,970 common shares, priced at $ 1.20 per share, priced at at the market under Nasdaq rules. The gross proceeds of this offering to the Company were approximately $ 4.1 million, before the deduction of placement agent fees and other expenses related to the offering payable by the Company. In a concurrent private placement, the Company also issued to the same investors unregistered warrants to purchase up to a total of 1,707,485 common shares at an exercise price of $ 1.37 per share. . The warrants can be exercised upon their issuance and have a term of five and a half years.
HC Wainwright & Co. acted as the exclusive placement agent for the Offer.
The Company intends to use the net proceeds of the Offering for working capital purposes.
The ordinary shares described above (but not the warrants or the ordinary shares underlying the warrants) have been offered by the Company under a direct offer registered in accordance with a “shelf” registration statement. ”On Form S-3 (registration number 333 -234073), including a base prospectus previously filed with the Securities and Exchange Commission (the“ SEC ”) on October 3, 2019, which came into effect on October 19, 2019. December 2019. A final prospectus supplement and base prospectus relating to the registered direct offering has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov . Electronic copies of the Prospectus Supplement and accompanying Base Prospectus can also be obtained by contacting HC Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at 646-975- 6996 or by email. To firstname.lastname@example.org.
The warrants described above were offered in a private placement pursuant to Section 4 (a) (2) of the Securities Act of 1933, as amended (the “Act”), and the Regulation D promulgated thereunder and, together with the common shares underlying the warrants, have not been registered under applicable State Securities Act or laws. Accordingly, the warrants and the underlying common shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act. and applicable state securities laws.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal. prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.
Helomics applies artificial intelligence to its rich data collected on patient tumors to both personalize cancer therapies for patients and to spur the development of new targeted therapies in collaboration with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA / RNA and proteomic signatures, providing researchers with a tool to develop and study the types of cancer cells found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA-approved STREAMWAY system, which automates the collection, measurement and disposal of liquid wastes, including blood, irrigation fluids and others, within a medical facility, by through national and international divisions. Soluble Biotech is a supplier of soluble and stable formulations for proteins, including vaccines, antibodies, large and small proteins and protein complexes. For more information, please visit www.predictive-oncology.com.
Some of the matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties for the Company’s business that may cause actual results to differ materially from those anticipated by statements made here. These risks and uncertainties include: market and other conditions and the intended use of the net proceeds of the registered direct placement, a variety of other risks and uncertainties, including, among others, the factors discussed under the heading “ Risk factors ”in our documents filed with the SECOND. Unless expressly required by law, the Company disclaims any intention or obligation to update these forward-looking statements.
Investor Relations Contact: